Tag: OTCMKTS:MDIT News
MEDITE Cancer Diagnostics, Inc. Reports Profitable Q3 and Nine Month 2015 Results
ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the 'Company' / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results. (Press Release)
MEDITE Cancer Diagnostics obtains Mexican Tender for 31 Stainers and First Delivery of Manual Microtome to China
ORLANDO, Fla., Aug. 27, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with a the total retail value of approximately $600,000. This is the first major sale to Mexico for MEDITE. (Press Release)
MEDITE Cancer Diagnostics, Inc. Reports Second Quarter and Six Month 2015 Results
ORLANDO, Fla., Aug. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. ('Company,' OTCQB symbol: MDIT / OTCBB:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results. (Press Release)
